Singapore markets closed

Straits Times Index
3,331.70
+5.42(+0.16%)
S&P 500
5,464.34
-4.96(-0.09%)
Dow
39,000.10
-112.06(-0.29%)
Nasdaq
17,768.60
+50.94(+0.29%)
Bitcoin USD
61,813.04
+8.43(+0.01%)
CMC Crypto 200
1,279.70
-4.08(-0.32%)

ITCI Aug 2024 85.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

1.1000

-1.0000

(-47.62%)

As of 11:47AM EDT. Market open.

Zacks
Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
Zacks
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
Zacks
Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.